ADC THERAPEUTICS SA

Insightful insider activity at ADC Therapeutics shows board confidence in its ADC cancer pipeline while routine tax‑sales keep liquidity tight—key for investors tracking upcoming clinical milestones.

Redmile Group’s $75M sell‑off of ADC Therapeutics shares highlights a strategic shift, while the firm’s promising TNBC ADC pipeline and Breakthrough Therapy status promise potential upside for investors and clinicians alike.